Modafinil vs Armodafinil — Key Takeaways: R-Enantiomer, Late-Shift Coverage, and Bipolar Safety

📇 The Index Card — Key Takeaways

Modafinil (Provigil) vs Armodafinil (Nuvigil)

The case — Betty, 32. A PMHNP working rotating 7 p.m.–7 a.m. ED nights (4–5 permanent nights a month) with bipolar I disorder and residual depression despite 6 weeks of lithium 900 mg daily (level 0.8). She has severe 3–6 a.m. brain fog, near medication errors, fragmented 4–5 hours of daytime sleep, an Epworth score of 16 — and she has nodded off at red lights twice in the past month on her 45-minute commute. She cannot switch to days for financial reasons.

1. The enantiomer is the whole difference. An enantiomer is a mirror-image version of the same molecule — same atoms, mirrored geometry, different behaviour in the body. Modafinil (Provigil) is the R + S pair together; armodafinil (Nuvigil) is the R-enantiomer only — modafinil's longer-acting half, isolated.
2. S clears fast; R holds the tail. In modafinil, the S enantiomer is eliminated in about 4 hours, giving biphasic (two-phase) elimination and a mid-to-late dip. Armodafinil's R-only profile eliminates monophasically (one phase) and, in the steady-state pharmacokinetic analysis NP Z cites (healthy men, dose-normalised to 200 mg/day), average plasma concentrations over 7–11 hours post-dose were roughly 44% higher than modafinil's.
3. Match the curve to 3–6 a.m. Both options are dosed 1 hour before the shift — modafinil 200 mg vs armodafinil 150 mg — and modafinil is a reasonable choice for many patients. Betty's impairment is not evenly spread, though: it concentrates in her last medication passes, 3–6 a.m. Armodafinil's tail still covers that window; modafinil's curve sags exactly there.
4. Wakefulness, not stimulation. Both agents mildly block the dopamine transporter (the pump that recycles dopamine) — without the vesicular dopamine release amphetamines cause, where stored dopamine is dumped into the synapse. NP Z's framing: they act more selectively on sleep–wake circuitry than on the reward centre (the nucleus accumbens), which is why he places their abuse potential below classic stimulants.
5. Raising lithium misses the centre of gravity. Betty's lithium level is already therapeutic at 0.8, with no pressured speech, impulsivity, or other sign that mania is unregulated — her complaint centres on sleepiness, focus, and cognition, not mood dysregulation. Pushing lithium toward 1.0–1.2 risks cognitive dulling and tremor, the opposite of what a clinician passing medications at 4 a.m. needs.
6. Quetiapine after the shift backfires. Adding quetiapine (Seroquel) 50 mg at daytime bedtime leans on its antihistamine (H1-blocking, sedating) effect to deepen sleep. NP Z's verdict: expect carryover grogginess — a groggier commute and a less alert next shift — worsening the very sleepiness it was meant to fix.
7. Bipolar is a monitor, not an automatic no. Activation is a reasonable theoretical concern, and NP Z keeps the mood-stabiliser foundation in place. But he notes these agents are commonly used adjunctively in bipolar depression, meta-analyses discussed in the episode show positive effects on fatigue and depression scores, and studies to date have not shown an increased risk of mood switch — which is not the same as impossible, so mood monitoring stays on the plan.

The call for Betty: Armodafinil 150 mg, taken 1 hour before each night shift. Two guardrails from the episode — no wake-promoting drug is a substitute for sleep (sleep hygiene and CBT-I, therapy for insomnia, stay on the plan), and cost and insurance coverage can change the real-world choice even when the pharmacology is clear.